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UrineAbstract A sensitive and speciﬁc fast gas chromatography–mass spectrometry (FGC–MS) analyt-
ical method using hydrogen as a carrier gas is developed for the rapid simultaneous determination
of morphine, codeine, hydrocodone and hydromorphone in human urine. Urine samples were
spiked with deuterated internal standards, morphine-d3, codeine-d3, hydrocodone-d3 and hydro-
morphone-d3, subjected to acid hydrolysis, treated with hydroxylamine to convert the keto-opiates
to oximes and then extracted using a positive pressure manifold and silica based solid phase extrac-
tion columns. The extracts were derivatized using BSTFA with 1% TMCS.
Gas chromatographic–mass spectrometric analysis was performed in electron ionization mode by
selective ion monitoring, using hydrogen as a carrier gas, a short narrow bore GC capillary column,
and fast temperature program, allowing for a rapid analytical cycle to maximize the instrument time
for high throughput laboratories. While maintaining speciﬁcity for these drugs, concentrations in
human urine ranging from 50 to 5,000 ng/mL can be measured with intraday and interday impre-
cision, expressed as variation coefﬁcients, of less than 2.3% for all analytes within a run time of less
than 3.5 minutes.
ª 2014 The International Association of Law and Forensic Sciences (IALFS). Production and hosting by
Elsevier B.V. All rights reserved.1. Introduction
Codeine andmorphine are naturally occurring alkaloids derived
from the seedpod of the opium poppy while hydrocodone and
hydromorphone are semi-synthetic opiate derivatives and her-
oin is a diacetyl derivative ofmorphine. The opiates are classiﬁedas narcotic analgesics with codeine, hydrocodone and hydro-
morphone additionally having antitussive properties. Heroin,
a Schedule I Controlled Substance in theUnited States, is gener-
ally administered by intravenous or subcutaneous injection, or
less frequently by smoking or nasal insufﬂation. Morphine,
codeine, hydrocodone and hydromorphone are Schedule II
Controlled Substances. Morphine can be administered by intra-
venous, intramuscular, or oral routes, while codeine, hydroco-
done and hydromorphone are usually administered orally.
Pharmacologic effects of the opiates, in addition to analgesia,ll rights
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depression, and constipation at therapeutic dosages. Overdose
ofmorphine/heroin can cause coma1 anddeath by cardiopulmo-
nary collapse2 and an overdose of codeine can cause uncon-
sciousness and convulsions; death may result from respiratory
failure.3 Toxic effects of hydrocodone and hydromorphone
include stupor, muscle ﬂaccidity, respiratory depression, hypo-
tension, cold and clammy skin and coma.4
Morphine is rapidly absorbed in the body. Plasma peak lev-
els following an oral dose occur after 15–60 min, and following
injection can occur after 15 minutes.5 Extensively metabolized
by the liver, only 2–12% is excreted as unchanged drug, while
60–80% is excreted as morphine-3-glucuronide. The elimina-
tion half-life of morphine ranges from 1 hour to 8 hours. Her-
oin is rapidly metabolized (plasma half-life is approximately
3 minutes), ﬁrst to monoacetylmorphine and further to mor-
phine. Morphine is the primary metabolite excreted in urine
after heroin abuse. Approximately 7% is excreted as
unchanged morphine and 50–60% as glucuronides. Addition-
ally, the speciﬁc heroin metabolite, 6-monoacetylmorphine
(6-MAM) may be detected in urine 4 h–8 h after the ingestion
of heroin. Codeine is also rapidly absorbed and metabolized
following an oral dose, principally to codeine-6-glucuronide,
with 10%–15% metabolized to morphine and norcodeine;
5%–17% of the codeine dose is excreted as a free drug.
Hydrocodone is more toxic than codeine and metabolized
in the liver with most metabolites being pharmacologically
active. About 26% of a single dose is eliminated in the 72 h
urine as unchanged drug. Hydromorphone is metabolized in
the body to hydromorphone-3-glucuronide and hydromor-
phol. About 6% of an average dose is excreted as free and
30% as conjugated hydromorphone in the 24 h urine. Opiates
may be detected in the urine for 24 h–72 h following ingestion.
The opiates/opioids are encountered frequently in forensic
toxicology as they are heavily prescribed and abused. The recent
upsurge in pain clinics throughout the United States and the dis-
pensing of large quantities of oxycodone and hydrocodone fur-
ther highlights the forensic importance of this drug class.6–8
According to the Centers for Disease Control and Prevention
(CDC), 100 people in the United States die from drug overdoses
every day, anddeath rates as a result of drugoverdoses havemore
than tripled since 1990. The CDC also reports that nearly three
out of four prescription drug overdoses are caused by opiates.
Drug testing for opiates under theMandatoryGuidelines for
Federal Workplace Drug Testing Programs9 in the United
States currently requires immunoassay screening and conﬁrma-
tion by gas chromatography–mass spectrometry (GC–MS) or
the recently approved technique of liquid chromatography–
mass spectrometry (LC–MS) for morphine and codeine. Sub-
stanceAbuse andMental Health Services Advisory (SAMHSA)
is proposing the addition of hydrocodone and hydromorphone
to thismandatory testing program.The immunoassays available
for opiate testing have variable cross-reactivity to codeine, mor-
phine, and other opiates.10 Detection and quantitation of keto-
opiates like hydrocodone, hydromorphone, oxycodone, and
oxymorphone are desirable (1) because of their potential inter-
ference with the measurement of codeine and morphine and
(2) because of their increasing potential for abuse.
Recent advances in instrumentation like liquid chromatog-
raphy with tandem mass spectrometry (LC–MS–MS) have
demonstrated simultaneous detection of naturally occurring
opiates and their synthetic derivatives such as hydrocodoneand hydromorphone in various matrices,11–14 but this instru-
mentation is more expensive than traditional electron impact
gas chromatography (EI-GC)–MS systems and may be cost-
prohibitive in many toxicology laboratories.
Several GC–MS methods have been developed for the anal-
ysis of codeine, morphine, and/or other opiates. The extrac-
tion, derivatization, and detection details of many of these
methods have been published in review articles.15,16 Stability
and characteristics of various derivatives used for opiate
anal-ysis17,18 as well as the hydrolysis efﬁciency of acid and
enzymes have also been studied.19
Problems encountered inGC–MSmethods for simultaneous
analysis of morphine and codeine include interference from
keto-opiates like hydrocodone, hydromorphone, oxyco-done
and oxymorphone in the analysis of codeine and morphine,
incomplete derivatization, instability of derivatives, poor chro-
matography, inefﬁcient hydrolysis, especially in case of enzyme
hydrolysis, and extended run times. Techniques to improve sep-
aration of these opiates include pretreatment with borohy-
dride,20 sequential derivatization,21 and multiple ramp
temperatures.22 Several methods have been reported that utilize
dual derivatization with hydroxylamine to form oxime deriva-
tives of the keto-opiates followed with BSTFA treat-ment.23–26
Others have used methoxyamine and propionic anhydride with
pyridine as a catalyst27 for derivatization or a three step deriva-
tization with methoxyamino/propionyl/ TMS groups.28
The method presented here is a modiﬁcation of previously
published methods that utilized hydroxylamine, and was devel-
oped to address the high throughput laboratory needs for fas-
ter turnaround times that the previously reported GC–MS
methods did not address. The procedure includes acid hydro-
lysis of urine samples followed by reaction with hydroxyl-
amine, extraction on solid-phase columns, and derivatization
with N,O-bis(trimethylsilyl)triﬂuoroacetamide (BSTFA).
Codeine, morphine, hydrocodone, and hydromorphone are
separated using a short, narrow bore capillary column, fast
temperature programing and hydrogen as a carrier gas, within
3.5 min, and without cross-interference. Quantitation was per-
formed with deuterated internal standards in selected ion mon-
itoring (SIM) mode.2. Materials and methods
2.1. Reagents and consumables
Certiﬁed drug-free urine was obtained from UTAK Laborato-
ries (cat# 88121-CDF). BSTFA with 1% TMCS was purchased
from Pierce Chemical Company (Rockford, IL). Hydroxyl-
amine hydrochloride was obtained from Sigma Chemical Com-
pany (cat# H-9876). Sodium phosphate, mono-basic,
monohydrate and sodium phosphate, dibasic, anhy-drous
(cat# 3818–01 and 38828–01) were purchased from J.T. Baker
(Phillipsburg, NJ). Hydrochloric acid, acetic acid, ammonium
hydroxide, methanol, dichloromethane, and isopropyl alcohol
were obtained from Spectrum Chemicals (Gardena, CA). All
solvents were of HPLC grade or better and all chemicals were
of ACS grade. Solid phase extraction columns (Clean Screen)
were obtained from United Chemical Technologies, Bristol,
PA. Gas chromatographic capillary column (CP-SIL 5CB,
cat# CP7684) was obtained from Agilent, Inc. (Lake Forest,
CA).
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The deuterated internal standards, codeine-D3, morphine-D3,
hydrocodone-D3 and hydromorphone-D3 (1 mg/mL in metha-
nol) as well as the unlabelled drugs (1 mg/mL in methanol)
codeine, morphine, hydrocodone and hydromorphone were
obtained fromCerilliant (RoundRock, TX). Themixed internal
standard solution containing all the deuterated analogs was pre-
pared in methanol at a concentration of 2000 ng/mL. Calibra-
tors were prepared from a mixed working stock solution of
codeine, morphine, hydrocodone and hydromorphone in
drug-free urine at a concentration of 5000 ng/mL. Stock refer-
ence material (1 mg/mL in methanol) of each opiate was also
obtained from an alternative manufacturer (Alltech, Deerﬁeld,
IL) for preparation of low and high positive controls, at concen-
trations of 250 and 2000 ng/mL, respectively, in drug-free urine.
A separate carryover control was prepared at 20,000 ng/mL in
drug-free urine. The solutions were stored at 20 C when not
in use. Drug-free negative, low and high positive controls and
the carryover control were included in every batch for analysis.
2.3. Preparation of working reagents
6 N hydrochloric acid: 400 mL of de-ionized water was added
to a 1 L volumetric ﬂask and 500 mL of concentrated hydro-
chloric acid was slowly added to the ﬂask. The contents were
diluted to 1 L with de-ionized water.
7.4 N ammonium hydroxide: 200 mL of de-ionized water
was added to a 500 mL volumetric ﬂask and 250 mL of con-
centrated ammonium hydroxide was slowly added to the ﬂask.
The contents were diluted to 500 mL with de-ionized water.
0.1 M phosphate buffer: pH 6.0: 2.93 g of sodium acetate
and 1.62 mL of glacial acetic acid were added to a 500 mL vol-
umetric ﬂask containing 400 mL of de-ionized water and then
diluted to 500 mL with de-ionized water. The pH was adjusted
to 4.5 ± 0.1.
0.1 M acetate buffer: pH 4.5: 12.14 g of monobasic sodium
phosphate and 1.7 g of dibasic sodium phosphate were added
to a 1 L volumetric ﬂask and diluted to 1 L with de-ionized
water. The salts were dissolved by shaking the ﬂask.
10% hydroxylamine hydrochloride: 10 g of hydroxylamine
hydrochloride was added to 100 mL volumetric ﬂask and
diluted to 100 mL with de-ionized water.
Elution solvent: Elution solvent was prepared by adding
2 mL of concentrated ammonium hydroxide to 20 mL of iso-
propyl alcohol, mixing and adding 80 mL of dichloromethane.
2.4. Sample preparation
Calibrators were prepared from the 5000 ng/mLmixed work-ing
stock solution in 1 mL drug-free urine at concentrations of 100,
250, 500, 1000 and5000 ng/mL for all analytes. 0.2 mLof internal
standard (mixed deuterated opiates) solution was added to all
tubes. The samples were subjected to acid hydrolysis before solid
phase extraction to release the free drugs from their conjugates.
2.5. Hydrolysis method
1 mL of 6 N hydrochloric acid was added to 1 mL urine. The
contents were mixed and the tubes were incubated at 120 Cfor 30 min. The samples were allowed to cool to room temper-
ature before extraction.
2.6. Conversion of keto-opiates to oximes
0.5 mL of 7.4 N ammonium hydroxide and 0.5 mL of 10%
hydroxylamine solution were added to the specimens in order
to convert the keto-opiates to their oximes prior to extraction
and to eliminate interference with morphine and codeine. The
specimens were vortexed and incubated at 70 C for 15 min.
Additional 0.5 mL aliquot of 7.4 N ammonium hydroxide
was added after allowing the samples to cool to room temper-
ature to bring the pH between 6 and 8.
2.7. Extraction procedure
The samples were extracted using solid phase extraction. 2 mL
of 0.1 M phosphate buffer (pH 6.0) was added to all the spec-
imens before extraction. The extraction columns were condi-
tioned by sequentially passing through 2 mL of methanol,
2 mL of de-ionized water and 2 mL of 0.1 M phosphate buffer
(pH 6.0). Samples were then loaded on to the extraction col-
umns and washed sequentially with 3 mL of de-ionized water,
3 mL of acetate buffer (pH 4.5) and 3 mL of methanol. The
columns were dried for 5 min under air pressure (25–30 psi)
before eluting the drugs with 2 mL of freshly prepared elution
solvent (methylene chloride: isopropanol: ammonium hydrox-
ide, 80:20:2 v/v). The solvent was evaporated to dryness under
a gentle stream of air at room temperature, followed by the
addition of 50 lL of the derivatizing reagent (BSTFA with
1% TMCS) and 50 lL ethyl acetate. The tubes were brieﬂy
vortexed and incubated at 70 C for 20 min. The samples were
transferred to auto sampler vials after cooling to room temper-
ature, and subsequently injected into the GC–MS system.
2.8. Gas chromatography–mass spectrometry
A Shimadzu QP 2010S gas chromatograph with a 220 V oven,
capable of fast temperature programming, coupled to an inert
mass selective detector, operating in electron impact mode,
was used for analysis. Hydrogen generated by a Parker Balston
hydrogen generator (Model# 920071) was used as a carrier gas
at a constant ﬂow of 1 mL per minute. The GC column dimen-
sions were 10 m 0.15 mm, ﬁlm thickness 0.12 lm, and the
injector was operated in splitless mode at 250 C. The oven
temperature program was initiated at 150 C (held for
0.5 min), and ramped to 300 C at a rate of 40 C/min. The
selected ions monitored for the deuterated internal standard
and all the analytes, along with their retention times, are indi-
cated in Table 1.
2.9. Data analysis
Calibration was carried out using least squares linear regres-
sion analysis over a concentration range of 100–5000 ng/mL.
Shimadzu Solutions software automatically calculated the
peak area ratios of target analytes and the internal standard
for each calibrator concentration. The data was ﬁt to a linear
regression curve with equal weighting. Morphine, codeine,
hydromorphone and hydrocodone were conﬁrmed quantita-
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resulting ion ratios were required to be within ± 20% of those
of the 100 ng/mL calibration standard for acceptance. In addi-
tion, a retention time window of ± 2.5% of the mean calibra-
tor retention time was required for acceptance of control and
unknown peaks. Quantitation of positive controls was
required to be within 20% of the established mean for each
control for analytical run acceptance.
2.10. Speciﬁcity
Five drug-free urines were collected from laboratory volunteers.
A 2 mLaliquot of each urine sample was extracted and analyzed
as described, in order to detect any potential interference from
endogenous compounds in the urine. Additionally, 2 mL of
drug-free urine was spiked with 10,000 ng/mL of cathinone,
diphenhydramine, doxylamine, desmethylsegiline, ephedrine,
fenﬂuramine, methylphenidate, methylaminorex, mescaline,
amphetamine, methamphetamine, MDMA, MDA, MDEA,
MBDB, BDB, methoxymethamphetamine, methoxyamphet-
amine, pseudoephedrine, phentermine, phenmetrazine, pro-
poxyphene phenylpropanolamine, nor-propoxyphene,
dihydrocodeine, norcodeine, normorphine, cis-tramadol, meth-
adone, N-desmethyl-cis-tramadol, methadone, dihydromor-
phine, oxymorphone, meperidine, normeperidine,
buprenorphine, norbuprenorphine, dextro-methorphan, mep-
robamate, methylphenidate, fentanyl, nor fentanyl, nalorphine,
naltrexone, naloxone, ketamine, nor ket-amine, nordiazepam,
temazepam, 2-hydroxy-ethyl-ﬂurazepam, 7-aminoﬂunitraze-
pam, oxazepam, alpha-hydroxy-alprazolam, lorazepam, 7-
aminoclonazepam, alpha-hydroxy triazolam, PCP, butalbital,
secobarbital, amobarbital, phenobarbital, pentobarbital, benz-
oylecgonine, cocaine, trazodone, hydrox-ybupropion, ﬂuoxe-
tine, norﬂuoxetine, pentazocine, dextro-phan, citalopram,
sertraline, nor-sertraline, butorphanol, carbamazepine, nalbu-
phine and paroxetine. The spiked urine samples were extracted
and analyzed as described to access potential interference in
terms of co-elution and quantitative accuracy.
2.11. Linearity and sensitivity
Drug-free urine was spiked with morphine, codeine, hydro-
morphone and hydrocodone at 50, 100, 250, 500, 1000, 2500,
5000, 10,000, 20,000 and 50,000 ng/mL to determine the range
of linearity. The limit of quantitation (LOQ) of the method
was deﬁned as the lowest concentration of analyte in the sam-
ple that could be quantitatively detected within ± 20% of theTable 1 Ions used for SIM analysis of opiates and the internal
standards used.
Analyte Ions Retention time
Target ion Qualiﬁer ions
D3-codeine 374 346 2.73
Codeine 371 343, 234 2.76
D3-morphine 432 417 2.93
Morphine 429 414, 287 2.95
D3-Hydrocodone 300 389 3.06
Hydrocodone 297 386 3.07
D3-hydromorphone 358 447 3.12
Hydromorphone 355 444, 429 3.13expected value, with a signal-to-noise ratio (peak height) in
excess of 10, and be within retention time (±2.5% of the cal-
ibration standard) and ion ratio (±20% of the calibration
standard) acceptance criteria. The limit of detection (LOD)
was deﬁned as the lowest concentration of an analyte that
could be qualitatively detected and maintain retention time,
ion ratio, and chromatography acceptance criteria. Five repli-
cates of each concentration level were analyzed to determine
the LOD and LOQ of the assay.
2.12. Imprecision
Imprecision was expressed as the percent relative standard
deviation for a statistically signiﬁcant number of samples.
Imprecision, in terms of coefﬁcient of variation, was deter-
mined at three levels for each analyte. The specimens, fortiﬁed
with all opiates at concentrations of 100, 250 and 500 ng/mL
were prepared. Five replicates of each concentration were ana-
lyzed according to the described procedure within a day (inter-
day imprecision) and for ﬁve consecutive days (intraday
imprecision).
2.13. Stability of opiates in urine as derivatized extracts
Stability of the derivatized extracts was investigated. Previ-
ously analyzed sample vials containing derivatized extracts
were left on the instrument auto sampler exposed to light
and room temperature for a period of two days and then re-
analyzed. Any change in the concentration between the days
was noted.
2.14. Application to authentic specimens
Specimens routinely received in the laboratory screening posi-
tive for opiates by enzyme immune assay were analyzed using
the described protocol. A comparison was drawn between the
quantitative results obtained from the conventional GC–MS
method utilizing a 30 m capillary column and FGC–MS (Fast
GC–MS) to determine the suitability of the new method.
3. Results and discussion
3.1. Method validation
The method for the detection of opiates was validated using
drug-free urine fortiﬁed with various concentrations of the
analytes as described. Authentic biological urines, with high
drug concentrations, were diluted into the linear range of the
assay.
3.2. Speciﬁcity
No endogenous interference was noted from biological drug-
free urine extracts and no exogenous interference from the
spiked drugs was noted in the assay.
3.3. Linearity and sensitivity
Linearity was observed from 100 to 5000 ng/mL for all opiates
analyzed. The linear regression equations of calibration curves,
Table 2 Limits of detection, limits of quantitation and calibration curve equations for opiates in urine.
Analyte LOD* (ng/mL) LOQ* (ng/mL) Linear equation** (y= response ratio) Correlation, r2
Codeine 50 100 y= 1.160x  0.0752 0.999
Morphine 50 100 y= 1.580x  0.1650 0.999
Hydrocodone 50 100 y= 1.420x  0.1650 0.998
Hydromorphone 50 100 y= 0.470x  0.0458 0.999
* Reported LOD/LOQ values are based on ﬁve determinations at each concentration.
** Linear equation based on six concentrations ranging from 100 to 5000 ng/mL.
Table 3 Inter-day (n= 5) and intra-day (n= 5) imprecision for the determination of opiates in urine.
Analyte CV (%) at 100 ng/mL CV (%) at 250 ng/mL CV (%) at 500 ng/mL
Intra Inter Intra Inter Intra Inter
Codeine 0.7 0.7 0.5 1.1 0.6 1.5
Morphine 1.9 2.3 0.7 1.7 0.9 1.2
Hydrocodone 1.5 1.3 1.0 0.8 0.5 1.1
Hydromorphone 1.4 2.3 1.5 2.0 1.3 1.4
Table 4 Stability of the derivatized opiate extracts after 24 h and 48 h.
Analyte Conc. spiked Conc. at 0 min Conc. at 24 h Conc. at 48 h Mean STD CV%
Codeine 100 100 99.8 100.1 99.97 0.12 0.12
200 200.6 199.7 200 200.10 0.37 0.19
500 502.2 502.4 502.5 502.37 0.12 0.02
Morphine 100 100 99.9 99.8 99.90 0.08 0.08
200 200.6 200.4 200.08 200.36 0.21 0.11
500 502.7 502.4 501.7 502.27 0.42 0.08
Hydrocodone 100 100 100 99.6 99.87 0.19 0.19
200 200.1 199.9 200.5 200.17 0.25 0.12
500 504.4 501.9 502.3 502.87 1.10 0.22
Hydromorphone 100 99 100 99.8 99.60 0.43 0.43
200 200.3 200.3 200.05 200.22 0.12 0.06
500 502.9 502.5 502.2 502.53 0.29 0.06
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are presented in Table 2.
3.4. Imprecision
Interday and intraday imprecision expressed as coefﬁcient of
variation (CV) for all analytes was less than 2.3%. Values at
three different concentrations for all four analytes are pre-
sented in Table 3.
3.5. Stability of opiates in urine as derivatized extracts
Derivatized extracts were found to be stable at room tempera-
ture for up to 48 h. Mean recovery, standard deviation and
CVs from the stability studies are presented in Table 4.
3.6. Application to authentic specimens
The newly developed procedure was applied to 76 clinical spec-
imens previously analyzed by the laboratory using a more con-
ventional method utilizing a 30 m GC column (DB-5 with
0.25 mm i.d.) and helium as the carrier gas. The resultsobtained with the two methods were compared and are shown
in Table 5. It is evident from the table that the results obtained
from the two methods are reproducible.
The sample analysis time with the conventional method uti-
lizing a 30 m column and helium as the carrier gas was 10 min
with the cycle time being 15 min whereas with the new method
utilizing fast chromatography achieved by using a much
shorter, narrow bore column and hydrogen as the carrier
gas, the sample analysis time was reduced to 3.5 min/sample
with the cycle time being 6 min. Sample throughput was more
than doubled by utilizing this method thereby optimizing the
instrument productivity. A typical total ion chromatogram
(TIC) showing separation of all four opiates is presented in
Figure 1
Opiate testing for morphine and codeine is performed rou-
tinely in forensic urine drug-testing laboratories in an effort to
identify illicit opiate abusers. In addition to heroin, the 6-keto-
opioids, including hydromorphone and hydrocodone, have
high abuse liability and are self-administered by opiate abus-
ers. This makes opiates one of the most frequently tested
and detected substances in drug testing cases. Having a fast,
high throughput method for quantitation in biological ﬂuids
is much needed for this high volume assay. The current
Table 5 Clinical sample results from conventional verses fast method.
Sample # Conventional method Fast method
Codeine Morphine HYC HYM Codeine Morphine HYC HYM
1 10,080 1081 9879 958
2 281 1867 258 1755
3 1201 1194
4 100 101 107 104 103 111
5 1688 165 1584 177
6 161.8 456 142 417
7 94 872 98 872
8 362 334
9
10 536 470
11 1087 1546 979 1586
12 1893 1184 1783 1170
13 748 168 665 181
14 780 284 718 318
15 324.6 292
16 215 202
17 3831 508 3899 479
18 2197 188 2084 221
19 10,030 1680 8979 1525
20 115 272 121 240
21
22 180 196 205 179
23 289 140 296 147
24 599 160 626 142
25
26 95 110
27 276 398 271 254 426 262
28 3546 3706
29 975 157 1010 133
30 306 202 321 194
31 5454 3099 5400 3163
32 560 548
33 2357 2496
34 2580 188 2897.6 164
35 464 159 494 122
36 10,895 317 11,693 292
37 1278 1538.9
38 313 138 329 151
39 673 764
40 144 125
41 1214 399 1301 417
42 467 108 477 98
43 251 225
44 557 620
45 885 179 818 158
46 55 106 69 92
47 2140 230 2419 206
48
49 161 287 162 327
50 9346 1301 9762 1424
51 946 73 1057 70
52
53 1072 7552 147 1124 8419 136
54 1543 1266 1549 1394
55 4901 6577 1533 5538 6285 1569
56 137 3625 136 4107
57 6112 1249 6407 1373
58 271 332 270 313
59 1655 623 1674 644
60 7671 2552 8038 2693
61 1457 1207
62 234 230
63 139 135
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Table 5 (continued)
Sample # Conventional method Fast method
Codeine Morphine HYC HYM Codeine Morphine HYC HYM
64 4886 268 4388 247
65 10,074 1677 11,663 1637
66 4519 93 4104 88
67 253 196 248 180
68 625 584 616 567
69 264 335 250 309
70 2033 3259 241 413 2119 4174 219 422
71 201 605 289 514 200 689 279 510
72 12,542 9018 421 12,724 11,429 398
73 3883 3716
74 1647 567 1619 554
75 73 150 62.2 137
76 1501 735 1397 717
Figure 1 Total ion chromatogram.
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oratories but can easily be modiﬁed for other matrices.
4. Conclusions
Minor modiﬁcations in the previously published analytical
method coupled with a very short, narrow bore GC capillary
column and the use of hydrogen as the carrier gas led to exten-
sive improvement in the instrument throughout without sacri-
ﬁcing sensitivity and speciﬁcity of analysis.
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